Thomas K Kilvaer

List of Publications by Year
in descending order

37 papers	2,008 citations	304368 22 h-index	315357 38 g-index
39 all docs	39 docs citations	39 times ranked	3385 citing authors

#	Article	IF	Citations
1	A Pragmatic Machine Learning Approach to Quantify Tumor-Infiltrating Lymphocytes in Whole Slide Images. Cancers, 2022, 14, 2974.	1.7	5
2	Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer. British Journal of Cancer, 2021, 124, 1680-1689.	2.9	37
3	Overexpression of miR-20a-5p in Tumor Epithelium Is an Independent Negative Prognostic Indicator in Prostate Cancerâ€"A Multi-Institutional Study. Cancers, 2021, 13, 4096.	1.7	11
4	Digitally quantified CD8+ cells: the best candidate marker for an immune cell score in non-small cell lung cancer?. Carcinogenesis, 2020, 41, 1671-1681.	1.3	18
5	Differential prognostic impact of platelet-derived growth factor receptor expression in NSCLC. Scientific Reports, 2019, 9, 10163.	1.6	20
6	Prognostic Value of Macrophage Phenotypes in Resectable Nonâ€"Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry. Neoplasia, 2019, 21, 282-293.	2.3	117
7	LAG-3 in Nonâ€"Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival. Clinical Lung Cancer, 2018, 19, 249-259.e2.	1.1	48
8	Evaluation of tumor-infiltrating lymphocytes using routine H&E slides predicts patient survival in resected nonâ€"small cell lung cancer. Human Pathology, 2018, 79, 188-198.	1.1	49
9	A gender specific improved survival related to stromal miR-143 and miR-145 expression in non-small cell lung cancer. Scientific Reports, 2018, 8, 8549.	1.6	24
10	Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer. PLoS ONE, 2018, 13, e0192157.	1.1	35
11	CTLA-4 expression in the non-small cell lung cancer patient tumor microenvironment: diverging prognostic impact in primary tumors and lymph node metastases. Cancer Immunology, Immunotherapy, 2017, 66, 1449-1461.	2.0	69
12	Assessing PDL-1 and PD-1 in Nonâ€"Small Cell Lung Cancer: A Novel Immunoscore Approach. Clinical Lung Cancer, 2017, 18, 220-233.e8.	1.1	72
13	The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer. PLoS ONE, 2017, 12, e0181527.	1.1	18
14	The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival. British Journal of Cancer, 2016, 114, 1145-1151.	2.9	25
15	Prognostic relevance of estrogen receptor Î±, Î² and aromatase expression in non-small cell lung cancer. Steroids, 2016, 113, 5-13.	0.8	44
16	The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Nonâ€"Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 789-800.	0.5	401
17	Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Annals of Oncology, 2016, 27, 225-232.	0.6	147
18	Prognostic effect of intratumoral neutrophils across histological subtypes of non-small cell lung cancer. Oncotarget, 2016, 7, 72184-72196.	0.8	54

#	Article	IF	Citations
19	CD45RO+ Memory T Lymphocytes â€" a Candidate Marker for TNM-Immunoscore in Squamous Nonâ€"Small Cell Lung Cancer. Neoplasia, 2015, 17, 839-848.	2.3	62
20	Stromal CD8+ T-cell Densityâ€"A Promising Supplement to TNM Staging in Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 2635-2643.	3.2	269
21	Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival. BMC Cancer, 2015, 15, 441.	1.1	31
22	Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer - A Structured Review with Meta-Analysis. PLoS ONE, 2015, 10, e0132481.	1.1	11
23	Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers. PLoS ONE, 2015, 10, e0134965.	1.1	61
24	The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk. BMC Clinical Pathology, 2014, 14, 5.	1.8	17
25	Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas. BMC Clinical Pathology, 2013, 13, 9.	1.8	4
26	Prognostic Impacts of Hypoxic Markers in Soft Tissue Sarcoma. Sarcoma, 2012, 2012, 1-10.	0.7	19
27	High expression of CD20+ lymphocytes in soft tissue sarcomas is a positive prognostic indicator. OncoImmunology, 2012, 1, 75-77.	2.1	22
28	Prognostic impact of CD57, CD68, M-CSF, CSF-1R, Ki67 and TGF-beta in soft tissue sarcomas. BMC Clinical Pathology, 2012, 12, 7.	1.8	23
29	Prognostic Impact of Jab1, p16, p21, p62, Ki67 and Skp2 in Soft Tissue Sarcomas. PLoS ONE, 2012, 7, e47068.	1.1	33
30	Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomas. BMC Clinical Pathology, 2012, 12, 5.	1.8	32
31	Estrogen receptor and progesterone receptor are prognostic factors in soft tissue sarcomas. International Journal of Oncology, 2011, 38, 1031-40.	1.4	17
32	Fibroblast growth factor 2 orchestrates angiogenic networking in non-GIST STS patients. Journal of Translational Medicine, 2011, 9, 104.	1.8	17
33	The prognostic impact of Akt isoforms, PI3K and PTEN related to female steroid hormone receptors in soft tissue sarcomas. Journal of Translational Medicine, 2011, 9, 200.	1.8	20
34	Prognostic Impact of Lymphocytes in Soft Tissue Sarcomas. PLoS ONE, 2011, 6, e14611.	1.1	96
35	The Prognostic Impact of TGF-Î²1, Fascin, NF-ÎºB and PKC-Î¶ Expression in Soft Tissue Sarcomas. PLoS ONE, 2011, 6, e17507.	1.1	30
36	Platelet-Derived Growth Factors in Non-GIST Soft-Tissue Sarcomas Identify a Subgroup of Patients with Wide Resection Margins and Poor Disease-Specific Survival. Sarcoma, 2010, 2010, 1-10.	0.7	17

#	Article	IF	Citations
37	Profiling of VEGFs and VEGFRs as Prognostic Factors in Soft Tissue Sarcoma: VEGFR-3 Is an Independent Predictor of Poor Prognosis. PLoS ONE, 2010, 5, e15368.	1.1	32